Drug Profile
AP 1101
Alternative Names: AP-1101Latest Information Update: 05 Aug 2015
Price :
$50
*
At a glance
- Originator Ariel Pharmaceuticals
- Class Cytoprotectives; Neuroprotectants; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cognition disorders; Memory disorders
Most Recent Events
- 23 Sep 2011 Phase-II clinical trials in Neuroprotection/Cognition disorders (prevention) in USA (IV)